EMA Authorised: Ixchiq (Chikungunya virus, strain CHIKV LR2006-OPY1, live attenuated) — Valneva Austria GmbH

View source ↗

Summary

The European Medicines Agency authorised Ixchiq, a live attenuated chikungunya virus vaccine (CHIKV LR2006-OPY1) developed by Valneva Austria GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya

Drugs mentioned

• Ixchiq

Snippet

Status: Authorised. Therapeutic area: Chikungunya virus. MAH: Valneva Austria GmbH. Decision date: 12/09/2025